CIK 0001253689 · Non-accelerated filer<br>Smaller reporting company
CRESCENT BIOPHARMA, INC.
Sign in to watch- Ticker
- CBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Cayman Islands
- Entity type
- operating
- Phone
- 617-430-5595
- Business address
- 300 FIFTH AVENUE, WALTHAM, MA, 02451
- Former names
- GLYCOMIMETICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $285,501
- in 7 filings, $286K under 10b5-1 plans
Net −$285,501. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Brumm Joshua T −$160K Chief Executive Officer sold 3% of stake
- McNeill Jonathan −$77K President and COO sold 3% of stake
- Pinkas Jan −$12K Chief Scientific Officer sold 3% of stake
- Im Ellie Eunkyung −$11K Chief Medical Officer sold 3% of stake
- Bispham Barbara Harlin −$11K See Remarks sold 3% of stake
Reading 48 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-13 | BVF PARTNERS L P/IL 10% owner | Other acquisition · Pre-Funded Warrants to Purchase Common Stock | +304,098 | 304,098 | ||
| 2025-06-13 | BVF PARTNERS L P/IL 10% owner | Other acquisition · Pre-Funded Warrants to Purchase Common Stock | +257,515 | 257,515 | ||
| 2025-06-13 | BVF PARTNERS L P/IL 10% owner | Other acquisition · Pre-Funded Warrants to Purchase Common Stock | +25,944 | 25,944 | ||
| 2024-08-08 | Invus Public Equities, L.P. 10% owner | Sale | −260,873 | $0.19 | $50K | 6,317,565 |
| 2024-08-07 | Invus Public Equities, L.P. 10% owner | Sale | −61,488 | $0.18 | $11K | 6,578,438 |
| 2024-08-06 | Invus Public Equities, L.P. 10% owner | Sale | −55,732 | $0.18 | $10K | 6,639,926 |
| 2024-08-05 | Invus Public Equities, L.P. 10% owner | Sale | −164,523 | $0.19 | $31K | 6,695,658 |
| 2024-08-02 | Invus Public Equities, L.P. 10% owner | Sale | −286,200 | $0.20 | $57K | 6,860,181 |
| 2024-08-01 | Invus Public Equities, L.P. 10% owner | Sale | −63,564 | $0.22 | $14K | 7,146,381 |
| 2024-07-30 | Invus Public Equities, L.P. 10% owner | Sale | −756,835 | $0.22 | $167K | 7,209,945 |
| 2024-07-29 | Invus Public Equities, L.P. 10% owner | Sale | −363,949 | $0.24 | $86K | 7,966,780 |
| 2024-07-26 | Invus Public Equities, L.P. 10% owner | Sale | −258,335 | $0.24 | $62K | 8,330,729 |
| 2024-06-21 | Rock Edwin Chief Medical Officer | Purchase | +115,000 | $0.27 | $31K | 680,403 |
| 2024-06-20 | Rock Edwin Chief Medical Officer | Purchase | +190,000 | $0.25 | $48K | 565,403 |
| 2024-06-18 | Hahn Brian M. SVP Finance, CFO | Purchase | +17,500 | $0.25 | $4K | 70,643 |
| 2024-05-01 | Koenig Scott Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2024-05-01 | Goldberg Mark Alan Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2024-05-01 | PEARSON TIMOTHY R Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2024-05-01 | King Rachel K. Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2024-05-01 | Andrews Patricia S Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 |
Page 4 of 16 · 305 trades